Raymond James analyst John Ransom raised the firm’s price target on HCA Healthcare to $320 from $300 and keeps an Outperform rating on the shares. HCA’s Q1 results were ahead of Street expectations, and the quarter was aided by $145M of revenue related to prior periods, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HCA: